Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Other Non Operating Income: 2018-2025

Historic Other Non Operating Income for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to $3.2 million.

  • Arcturus Therapeutics Holdings' Other Non Operating Income fell 15.30% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year decrease of 26.17%. This contributed to the annual value of $15.2 million for FY2024, which is 55.25% down from last year.
  • Arcturus Therapeutics Holdings' Other Non Operating Income amounted to $3.2 million in Q3 2025, which was up 25.98% from $2.6 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year Other Non Operating Income high stood at $34.0 million for Q1 2023, and its period low was -$3.8 million during Q4 2022.
  • Its 3-year average for Other Non Operating Income is $6.5 million, with a median of $3.5 million in 2023.
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' Other Non Operating Income crashed by 2,281.82% in 2021 and then surged by 6,120.04% in 2023.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Other Non Operating Income (Quarterly) stood at -$524,000 in 2021, then plummeted by 631.87% to -$3.8 million in 2022, then skyrocketed by 113.80% to $4.0 million in 2023, then dropped by 4.09% to $3.2 million in 2024, then dropped by 15.30% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $2.6 million for Q2 2025, and $2.8 million during Q1 2025.